QIAGEN N.V. Reports Results for Third Quarter and First Nine Months of 2017

VENLO, the Netherlands, November 6, 2017 /PRNewswire/ --

        
        - Solid Q3 2017 performance in line with full-year ambitions: 
        - Net sales $364.0 million (+7% actual, +7% CER); adjusted net sales
          $364.4 million (+8% actual, +7% CER vs. +7% CER guidance) 
        - EPS $0.21; adjusted EPS $0.32 ($0.32 CER), adjusted EPS excluding
          restructuring charge $0.32 ($0.32 CER vs. $0.32-0.33 CER guidance) 
        - Nine-month 2017 free cash flow of $146.1 million impacted by $41 million cash
          restructuring charges 
        - Solid growth of Sample to Insight portfolio led by QuantiFERON latent TB test growing
          above 25% CER annual target, complemented by QIAsymphony, human ID / forensics and
          infectious disease testing portfolio 
        - $300 million share repurchase commitment completed ahead of end-2017 goal 
        - New initiative in China to focus on high-growth areas and streamline portfolio 
        - Reaffirming 2017 adjusted EPS target of $1.25-1.27 CER before restructuring;
          ~7% CER adjusted net sales growth excluding changes in China portfolio  

QIAGEN N.V.(NASDAQ: QGEN; Frankfurt Prime Standard: QIA) announced results of operations for the third quarter and first nine months of 2017, delivering on goals for improvements in adjusted net sales and adjusted earnings.

Click here for the full press release https://corporate.qiagen.com/newsroom/press-releases/2017/2017-11-06-Q3results?sc_lang=en

        

        Contacts 
        Investor Relations: 
        John Gilardi 
        Vice President Corporate Communications and Investor Relations 
        +49-2103-29-11711 
        +1-240-686-2222 

        Dr. Sarah Fakih 
        Associate Director Investor Relations 
        +49-2103-29-11457 
        Email: ir@qiagen.com 
        ir.qiagen. com


        Public Relations: 
        Dr. Thomas Theuringer 
        Senior Director Public Relations and Digital Communications 
        +49-2103-29-11826 
        +1-240-686-7425 
        Email: pr@qiagen.com 
        pr.qiagen.com 

http://www.twitter.com/qiagen 

http://www.facebook.com/QIAGEN 

Download the QIAGEN Investor Relations App

Apple: https://itunes.apple.com/us/app/qiagen-investor-relations/id1170201291?mt=8

Android: https://play.google.com/store/apps/details?id=com.theirapp.qiagen&hl=de

SOURCE QIAGEN N.V.